



**CONGRATULATIONS:  
THESUS-HF II STUDY ABSTRACT ACCEPTED  
HFA CONGRESS BELGRADE**

**MESSAGE FROM THE STUDY CHAIR**

Dear Investigators,

Congratulations to everyone! Three THESUS-HF II Study abstracts have been submitted, with one already accepted and awaiting confirmation for the others. Refer to the details provided below in the newsletter. Our heartfelt thanks go out to all the participating sites for their tremendous effort and dedication in making this study a success thus far.

**Deadline Reminder: End of patient recruitment of all 7 days - 31 March 2025**

The **PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria**, will take place **15 - 19 September 2025**. Please indicate by clicking on the link in the MEETINGS 2025 section below whether you would be able to attend and participate in the **Workshop THESUS-HF II Session on 16 September 2025** at the meeting.

Regards,

Karen Sliwa (THESUS-HF II Principal Investigator)


**ABSTRACTS SUBMITTED**

The THESUS-HF II Study abstracts were submitted to the following publications:

ACCEPTED for ESC HFA, Belgrade 17 - 20 May 2025:  
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):  
Access to Care

Submitted to ESC Congress, Madrid 29 Aug - 1 Sep:  
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):  
Aetiology, Acute Management and In-hospital Outcome

Submitted to Global Heart Journal:  
Generating important insights into the spectrum and outcomes of  
acute heart failure across the Africa continent: The Sub-Saharan  
Africa Survey of Heart Failure (THESUS-HF II)


**MEETINGS 2025**

Please click on the links to indicate your provisional attendance for each meeting in 2025 on the Meeting Survey Form. You may select more than one meeting if applicable.

[ESC Heart Failure 17 - 20 May 2025, Belgrade, Serbia](#)

[ESC Congress 29 August - 1 September 2025, Madrid, Spain](#)

[PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria  
15 - 19 September](#)

Kindly take note: A THESUS-HF II Study Session Meeting will take place during the PASCAR & 54th Annual General Meeting and Scientific Conference, providing an opportunity for you to present feedback and an abstract related to the THESUS-HF II Study.


**PATIENT DATA COLLECTION CONFIRMATION**

Please complete the Patient Data Collection Confirmation form, to indicate the number of days data collected:

[CLICK HERE TO COMPLETE](#)

**Deadline Reminder: End of patient recruitment of all 7 days - 31 March 2025**


**SITE INFORMATION**

Thank you for all that completed the site information, sites who have not uploaded their site information yet, please do so on REDCAP as soon as possible.


**UPTITRATION SUB-STUDY REDCap PORTAL**

**Usage and Dosing of Guideline-Directed Medical Therapies in African Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction**

Guidelines recommend starting and quickly increasing guideline-directed medical therapy (GDMT) within six weeks of heart failure (HF) hospitalization to reduce rehospitalization and mortality risk. However, there is a gap between these recommendations and actual practices, leaving many patients with HF<sub>r</sub>EF and HF<sub>m</sub>rEF in Africa on suboptimal therapy. This Sub-study aims to:

1. Assess the proportion of HF<sub>r</sub>EF and HF<sub>m</sub>rEF patients initiating ACEI/ARB/ARNI, MRA, beta-blockers, and SGLT2i before hospital discharge.
2. Evaluate initiation of these medications within 30 days of discharge.
3. Evaluate initiation within 60 days of discharge.
4. Determine the proportion achieving target doses of ACEI/ARB/ARNI, MRA, and beta blockers at 180 days post-discharge compared to baseline.



[CLICK HERE to complete Sub-Study information on REDCap](#)